

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/079,416	02/22/2002	Oliver Yoa-Pu Hu	39297-174170	8467	
²⁶⁶⁹⁴ 7590 09/10/2002 VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP			EXAMINER		
P.O. BOX 34385 WASHINGTON, DC 20043-9998			KIM, VICKIE Y		
	•		ART UNIT	PAPER NUMBER	
			1614		
			DATE MAILED: 09/10/2003	2 H	

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-326 (Rev. 04-01)	Office Action S	Summary		Part	of Paper No. 4
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing 3) Information Disclosure Statement(s) (PT S. Patent and Trademark Office	Review (PTO-948) O-1449) Paper No(s)	4)	Interview Summary (Notice of Informal Pa Other:	PTO-413) Paper Notent Application (PT	o(s) FO-152)
15) Acknowledgment is made of Attachment(s)	a claim for domestic pri	ority under 3	5 U.S.C. §§ 120 a	and/or 121.	
a) The translation of the fo					ai application).
* See the attached detailed Of 14) Acknowledgment is made of					al annlia-#:\
application from t	d copies of the priority d the International Bureau	(PCT Rule 1	7.2(a)).		i Stage
	e priority documents have				l Ctor-
	e priority documents have			n No	
a) ☐ All b) ☐ Some * c) ☐ N 1. ☐ Certified copies of the		.o.be	د د		
13) Acknowledgment is made of		onty under 35	5 U.S.C. § 119(a)-	-(d) or (f).	
Priority under 35 U.S.C. §§ 119 and					
12) The oath or declaration is of	_	ner.			
If approved, corrected drawing			tion.		
11) The proposed drawing corre				ed by the Exami	ner.
Applicant may not request the					
10) The drawing(s) filed on					
9)☐ The specification is objected	d to by the Examiner.				
Application Papers			=		
8) Claim(s) <u>1-16</u> are subject to		ion requirem	ent.		
7) Claim(s) is/are objective.					
6) Claim(s) is/are rejection					
5) Claim(s) is/are allow		om consider	auull,		
4)⊠ Claim(s) <u>1-16</u> is/are pendi 4a) Of the above claim(s) _		com conside	otion		
·	ng in the application				
closed in accordance with Disposition of Claims	the practice under $Ex \mu$	parte Quayle,	1935 C.D. 11, 4	53 O.G. 213.	
3) Since this application is in				reacution on to t	the merite is
2a) This action is FINAL .		ction is non-f	inal		
1) Responsive to communic	ation(s) filed as				
THE MAILING DATE OF THIS C - Extensions of time may be available under t after SIX (6) MONTHS from the mailing date - If the period for reply specified above, the - Failure to reply within the set or extended pe - Any reply received by the Office later than the earned patent term adjustment. See 37 CFF Status	he provisions of 37 CFR 1.136(a). e of this communication. than thirty (30) days, a reply within maximum statutory period will ap eriod for reply will, by statute, caus aree months after the mailing date	in the statutory min ply and will expire se the application t	nimum of thirty (30) days SIX (6) MONTHS from to become ABANDONED	will be considered tim he mailing date of this	ely. communication.
A SHORTENED STATUTORY P	ERIOD FOR REPLY IS	SET TO EX	PIRE <u>1</u> MONTH(S	S) FROM	
The MAILING DATE of this Period for Reply	s communication appears	s on the cove	r sneet with the co	orrespondence a	iddress
TI MAII NO DATE (III		ckie Kim		1614	
Office Action Sum	mary Ex	aminer		Art Unit	
	10	10/079,416		YOA-PU HU ET AL.	
	A	oplication No.		Applicant(s)	

Application/Control Number: 10/079,416 Page 2

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, drawn to a dermal cytochrome P450 1A(CYP1A) inhibitor.
- II. Claims 10-12, drawn to a method for treating patients with dermatological diseases comprising administering the said inhibitor of Group I.
- III. Claims 13-14, drawn to a method for treating skin cancer comprising topical administration of the said inhibitor of Group I.
- IV. Claims 15-16, drawn to a CYP1A enhancer.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions (I & IV) and (II-III) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)).
- 3. Inventions I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).
- 4. Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

· · Ληημοστία Application/Control Number: 10/079,416

Art Unit: 1614

5. Because these inventions are distinct for the reasons given above and have

Page 3

acquired a separate status in the art as shown by their different classification and the

search required for each group is not same, wherein a reference which anticipates the

invention of Group I would not render the invention of Group II, III or IV obvious, absent

ancillary art, restriction for examination purposes as indicated is proper. Even if there

were unity of classification, the search of entire groups and/or genus in the non-patent

literature(especially, non-patent literature) and database search (a significant part of a

thorough examination) would be burdensome, it is undue burden for examiner for the

accurate and proper examination, restriction for examination purposes as indicated is

proper.

6. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Vickie Kim whose telephone number is 703-305-1675.

The examiner can normally be reached on Tuesday-Friday. If attempts to reach the

examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel

can be reached on 703-308-4725. The fax phone numbers for the organization where

this application or proceeding is assigned are 703-746-3165 for regular communications

and 703-746-3165 for After Final communications. Any inquiry of a general nature or

relating to the status of this application or proceeding should be directed to the

receptionist whose telephone number is 703-308-1235.

William Jarvis

Primary Patent examiner

Vickie Kim, Patent examiner September 5, 2002 Art unit 1614 Application/Control Number: 10/079,416

Art Unit: 1614

Page 4